Daiichi Sankyo’s anti-clotting drug Savaysa gets FDA approval
Savaysa is an oral, once-daily selective factor Xa-inhibitor developed to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). Daiichi Sankyo
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.